Wai Yuen Tong Medicine Holdings (HKSE:00897) LT-Debt-to-Total-Asset : 0.13 (As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Wai Yuen Tong Medicine Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Wai Yuen Tong Medicine Holdings's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.13.

Wai Yuen Tong Medicine Holdings's long-term debt to total assets ratio declined from Sep. 2022 (0.18) to Sep. 2023 (0.13). It may suggest that Wai Yuen Tong Medicine Holdings is progressively becoming less dependent on debt to grow their business.

Wai Yuen Tong Medicine Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Wai Yuen Tong Medicine Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wai Yuen Tong Medicine Holdings LT-Debt-to-Total-Asset Chart

Wai Yuen Tong Medicine Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.18

0.15

0.11

0.14

0.15

Wai Yuen Tong Medicine Holdings Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.14	0.18	0.15	0.13

Wai Yuen Tong Medicine Holdings LT-Debt-to-Total-Asset Calculation

Wai Yuen Tong Medicine Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	1032.461	/	7013.815
	=	0.15

Wai Yuen Tong Medicine Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	877.709	/	6583.962
	=	0.13

Wai Yuen Tong Medicine Holdings (HKSE:00897) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Wai Yuen Tong Medicine Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Wai Yuen Tong Medicine Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Wai Yuen Tong Medicine Holdings (HKSE:00897) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wai Yuen Tong Medicine Holdings Ltd (HKSE:00897) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

39 Wang Kwong Road, Suite 3101, 31st Floor, Skyline Tower, Kowloon Bay, Kowloon, Hong Kong, HKG

Website

https://www.wyth.net

Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties in the agricultural produce market. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.

Executives

Wang On Group Limited	2501 Other
Tang Ching Ho	2501 Other
Yau Yuk Yin	2202 Interest of your spouse

Wai Yuen Tong Medicine Holdings (HKSE:00897) Headlines

No Headlines